Cargando…
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
PURPOSE: BRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for BRD9 in multiple cancer types including multiple myeloma, its clinical significance and oncogenic mec...
Autores principales: | Kurata, Keiji, Samur, Mehmet K., Liow, Priscilla, Wen, Kenneth, Yamamoto, Leona, Liu, Jiye, Morelli, Eugenio, Gulla, Annamaria, Tai, Yu-Tzu, Qi, Jun, Hideshima, Teru, Anderson, Kenneth C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150249/ https://www.ncbi.nlm.nih.gov/pubmed/36780189 http://dx.doi.org/10.1158/1078-0432.CCR-22-3668 |
Ejemplares similares
-
PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018) -
Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
por: Lynggaard, Charlotte Duch, et al.
Publicado: (2022) -
Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017) -
The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021) -
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
por: Monfrini, Chiara, et al.
Publicado: (2022)